Topic · 26 episodes
Health
Health in 2024 is being reshaped by precision medicine across several fronts. Onpode's coverage spans gene therapy for hereditary angioedema, a non-hormonal menopause treatment reducing hot flashes and mood symptoms, an oral GLP-1 pill delivering meaningful weight loss and blood sugar control, and the FDA's first targeted approval for PTEN-deficient prostate cancer. The through-line: treatments engineered for defined patient populations.
Frequently asked
What are the Phase 3 results for Intellia's lonvo-z gene therapy?
Intellia's lonvo-z posted strong Phase 3 results for hereditary angioedema treatment. The data marked a significant milestone for gene therapy in this rare genetic condition, suggesting lonvo-z could offer a durable intervention for patients managing hereditary angioedema.
Is there a menopause treatment that works without hormones?
A non-hormonal menopause treatment has shown in trials that it can reduce hot flashes, anxiety, and depression without the risks associated with hormone replacement therapy. This offers a meaningful alternative for people who cannot or prefer not to use HRT.
Can a pill replace injectable GLP-1 drugs for diabetes and weight loss?
A new GLP-1 diabetes pill has achieved significant weight loss and blood sugar control in clinical trials, suggesting an effective oral pill could be a viable alternative to injectable GLP-1 therapies for patients managing type 2 diabetes and obesity.
What is AstraZeneca's Truqap and what did the FDA approve it for?
AstraZeneca's Truqap received FDA approval as the first and only targeted treatment for PTEN-deficient prostate cancer. This approval represents a precision oncology advance, giving clinicians a specifically indicated option for a prostate cancer subgroup defined by PTEN loss.
Episodes
Screening bias — how finding disease early doesn't always improve outcomesEarly cancer screening can improve outcomes, but lead-time bias, length-biased sampling, and overdiagnosis mean five-year survival rates routinely overstate real benefit. Mammography requires screening over 1,300 women to prevent one breast cancer death, and between negligible and more than one in three screen-detected cancers may never have caused harm.
Universal access vs market efficiency — structural tradeoffs in health system designGermany spends 12.8% of GDP on healthcare — the highest share in the EU — yet still rations treatments available elsewhere. No health system simultaneously achieves universal access and market-driven innovation. OECD data confirm no model consistently dominates on all performance indicators; every country is choosing which form of inequality to accept.
How randomization eliminates bias — the mechanism that makes causation knowableRandomization eliminates confounding by distributing every variable — known and unknown — equally across trial groups by chance, not judgment. But this balance is guaranteed only in expectation across many trials, never in a single trial. That gap between the statistical promise and the one-trial reality medicine actually runs on is the core tension in evidence-based practice.
Why placebos activate real neural pathways — the mechanism behind expectationPlacebos activate real neural pathways: a 1978 naloxone study proved placebos trigger endogenous opioid release, not mere perception. PET imaging later showed expectation alone produces measurable dopamine in Parkinson's patients' depleted striatum. The effect is chemically real but bounded — prediction-sensitive systems respond; bacterial infections do not.
Dovato's two-drug regimen matched Biktarvy's three-drug combo in first-of-its-kind HIV treatment study — simpler may work as wellDovato, ViiV Healthcare's two-drug HIV pill, matched Gilead's three-drug Biktarvy in the VOGUE trial — 509 treatment-naïve adults, 48-week non-inferiority met. But Biktarvy holds 52% of the global market, guidelines haven't moved, and Gilead unveiled once-weekly ISL/LEN data at the same conference.
New research shows financial hardship may age the brain faster — what this means for millions facing economic pressureA UCL study tracking 2,759 people from birth found that persistent financial hardship between ages 26 and 53 is associated with measurable brain atrophy and enlarged ventricles by ages 69–71. Effects were strongest in men, those with childhood disadvantage, and APOE-ε4 carriers — but whether poverty causes the aging or merely marks earlier-loaded risk remains unresolved.
FDA advisory committee just voted to loosen restrictions on six wellness peptides flagged as serious safety risksAn FDA advisory panel voted 8–6 on July 23–24, 2026, to ease restrictions on six peptides — BPC-157, TB-500, KPV, MOTS-c, epitalon, and semax — despite the agency's own scientists raising safety concerns about all six. The vote is non-binding; FDA still controls the 503A Bulks List and has not yet acted.
New US cholesterol guidelines may qualify millions more Americans for statins — but eligibility expansion raises questions about who actually needs themThe 2026 ACC/AHA cholesterol guidelines make 87.5 million Americans — 56.6% of adults aged 30–79 — eligible for statins, adding 21.5 million new candidates. But a simultaneous JAMA editorial noted roughly half of those already eligible under 2018 rules weren't taking statins, raising a sequencing problem more than a medical one.
Why FDA approves drugs on surrogate endpoints before efficacy is provenIn July 2026, the FDA approved two drugs for IgA nephropathy in ten days using opposite evidence standards: Fabhalta (iptacopan) converted to full approval after two-year kidney outcome data; Trutakna (atacicept-vymj) received accelerated approval on a surrogate endpoint, with its label explicitly stating long-term kidney preservation has not been established.
Seven peptides face FDA review this week, but FDA scientists say there's little evidence they actually work in humansThe FDA's Pharmacy Compounding Advisory Committee is voting July 23–24, 2025 on whether seven peptides — including BPC-157 and TB-500 — can be mass-produced by compounding pharmacies, despite FDA staff scientists finding little to no human safety or efficacy evidence for any of them.
A daily polypill combining multiple medications just significantly improved cardiac function and cut hospitalizations in heart failure patientsA polypill combining guideline-directed heart failure medications — including metoprolol and lisinopril — cut hospitalizations and ER visits by 60% compared to standard multi-drug therapy in a Nature Medicine study led by Michigan Medicine and UT Southwestern. The gain came from adherence, not new chemistry: patients simply took all their medications.
FDA just approved Lipfendra, a once-daily pill that cuts bad cholesterol without injectionsLipfendra, FDA-approved July 16, is the first once-daily oral PCSK9 inhibitor cleared in the U.S., cutting LDL by up to 59% in trials. But approval rests on a surrogate endpoint — cardiovascular outcomes data confirming actual heart attack and stroke prevention is still pending.
Why your immune system tolerates your own cells but attacks invadersThe immune system tolerates its own cells through two layers: central tolerance in the thymus, where the AIRE gene lets thymic cells preview thousands of tissue antigens to delete self-reactive T cells, and peripheral tolerance, where Tregs and checkpoints manage escapees. Some self-reactive cells survive as an apparent trade-off to preserve repertoire breadth, though whether this is a selected feature remains unresolved.
Nearly half of women don't recognize perimenopause symptoms — what's driving this awareness crisisNearly 42% of women aged 40–44 cannot identify what reproductive stage they are in, according to a Flo Health and Mayo Clinic study of 7,640 women published in the journal Menopause. Perimenopause symptoms — mood swings, cognitive fog, disrupted sleep — are misread as anxiety or depression, leaving a hormonal transition unnamed and untreated for years.
XRHealth just acquired Swing Therapeutics to build the largest VR-based chronic pain platform — what that means for patientsXRHealth's acquisition of Swing Therapeutics, announced July 15, bundles Stanza — the only FDA De Novo–authorized prescription digital therapeutic for fibromyalgia — with VR headsets, smartwatches, and telehealth. The clinical evidence covers fibromyalgia alone; the marketing targets chronic pain broadly. No deal terms were disclosed, and no trial has tested the full bundle.
A Merck-partnered ADC just proved it can replace standard chemo in first-line lung cancer treatment — here's what changesSacituzumab tirumotecan (sac-TMT), Kelun-Biotech's TROP2-targeting ADC licensed to Merck for $1.4 billion, beat chemo-immunotherapy in first-line PD-L1-negative non-squamous NSCLC in the OptiTROP-Lung06 Phase 3 trial — but pembrolizumab (Keytruda) remained in both arms, meaning platinum was replaced, not Keytruda.
Celcuity's Revtorpyk just won FDA approval as the first pan-PI3K/mTOR inhibitor for advanced breast cancerGedatolisib (Revtorpyk) won FDA approval on July 14, 2026 as the first pan-PI3K/mTOR inhibitor for HR+/HER2-negative, PIK3CA wild-type advanced breast cancer — a population representing roughly 60% of HR+/HER2-negative cases that previously had no precision pathway. The VIKTORIA-1 trial showed 9.3 months median PFS versus 2 months on fulvestrant alone.
Why your body's 24-hour clock controls metabolism, immunity, and hormone timingRoughly 40% of the human genome is expressed on a 24-hour circadian schedule, and every organ — liver, pancreas, immune cells — runs its own molecular clock. When those clocks fall out of sync, the result is a distinct metabolic disease mechanism, separate from sleep loss, that degrades glucose tolerance, cortisol rhythm, and immune gating.
Ozempic and Wegovy mistakes are creating a poison control crisis — here's what's going wrongPoison control calls involving semaglutide — the active ingredient in Ozempic and Wegovy — reached 3,633 cases in just the first four months of 2025, up from under 1,500 annual calls before Wegovy's 2021 weight-loss approval. University of New Mexico Hospital data show 78% of cases involve incorrect dosing, including ten-fold overdoses.
Trutakna just became the first two-target treatment approved for IgA nephropathy — a major shift in kidney disease therapyTrutakna (atacicept), FDA-approved July 7, 2026 for IgA nephropathy, is the first treatment to block both BAFF and APRIL simultaneously. It cut Gd-IgA1 by 68% and reduced proteinuria 42% versus placebo in ORIGIN 3 — but approval rests on a surrogate endpoint; confirmatory kidney-function data are expected Q3 2026.
Northwestern study shows lung transplants dramatically extend survival in advanced lung cancer — upending treatment assumptionsA Northwestern Medicine study published in JAMA on July 8, 2026, found 100% one-year survival in select stage IV non-small cell lung cancer patients who received double lung transplants — though the comparison group fared worse and was not a matched control, and no long-term disease-free survival data yet exists.
Why your body resists change — the feedback loops that keep you aliveHomeostasis — named by Walter Cannon in 1926, conceived by Claude Bernard in 1865 — keeps blood glucose between 70–110 mg/dL and core temperature near 37°C through negative feedback loops: sensor, control center, set point, effector. During infection, the hypothalamus raises its set point, making a fever the defended value, not the malfunction.
Intellia's lonvo-z gene therapy posted strong Phase 3 results for hereditary angioedema treatment
A non-hormonal menopause treatment just reduced hot flashes, anxiety, and depression without HRT risks
A new GLP-1 diabetes pill just achieved major weight loss and blood sugar control in trials
AstraZeneca's Truqap just won FDA approval as the first and only targeted treatment for PTEN-deficient prostate cancer